Why the study?
Does prazosin improve haemodynamics in patients with severe congestive cardiac failure?
Does prazosin improve haemodynamics in patients with severe congestive cardiac failure?
Prazosin produces marked acute haemodynamic benefits in severe heart failure, but these effects attenuate during chronic therapy.
Answers are grounded in this paper and cite their sources.
Acute prazosin benefits in severe HF attenuate with chronic use; challenges sustained efficacy assumptions and supports dedicated outcome trials.
The acute effects of prazosin on resting and exercise haemodynamics were studied in 16 patients in hospital with severe congestive cardiac failure. After an oral dose of prazosin (3 to 5 mg), there was a significant improvement in cardiac function manifested by a reduction in left ventricular filling pressure at rest and during exercise, a rise in resting cardiac index, and an increase in exercise duration. The mean arterial pressure fell at rest, but not during exercise. No significant changes were observed in the resting or exercise heart rate, or in the cardiac index during exercise. Twelve of the 16 patients entered a chronic outpatient double-blind crossover study, in which four weeks' therapy with prazosin was compared with a four-week placebo period. Digoxin and diuretic therapy was continued unchanged throughout the eight-week study period. Clinical status and resting and exercise haemodynamics were assessed at each four-week period. Nine patients completed the trial. Two patients noted relief of symptoms on prazosin therapy, and seven patients noted no change. No side effects were reported. The haemodynamic changes in the “chronic” study were less marked than those observed in the “acute” study. Compared with measurements with placebo administration, prazosin produced a fall in resting mean arterial pressure, a small decline in resting left ventricular filling pressure and an increase in cardiac index during exercise. No significant changes were observed in resting cardiac index, mean arterial pressure during exercise, left ventricular filling pressure during exercise, or resting or exercise heart rate. Duration of exercise was not significantly increased by prazosin. It is concluded that prazosin produces marked acute beneficial haemodynamic effects due to combined arteriolar and venous dilatation in patients with congestive cardiac failure. During chronic therapy the beneficial haemodynamic effects are less marked and appear to be mainly due to arteriolar dilatation.
No takes yet. Share an insight, caveat, or question.
Harper et al. (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: